Building a Trusted Environment for Underrepresented People in Healthcare


Derek van Amerongen, MD, MSc: Is there anything very important that your organization is implementing in your organization from a colleague’s perspective or from the front line office to facilitate this for the benefit of our listeners?

Sharon Deans, MD, MPH, MBA: That’s a good question. I think the most important thing is what my doctor reports to me and that there are always questions when the clinical trial is completed. “Clinical trials are out of scope,” they say. And I say, “We don’t cover their medications, we don’t cover experimental treatments.” [treatment]However, it covers all services. ’ We root for them. If our members are selected for these trials, we will do everything in our power to support them in the course of their treatment so that we can all learn from it. We want to make sure everyone is well informed on the payer side and where we stand. I wonder if you bring this up because we just discussed this subject a few days ago if anyone knew we covered clinical trials and experimental therapy services. And we needed to keep people up to date to make sure everyone was well educated within the payer territories around it. And we study by ourselves. We have done some research on telemedicine and patient registration. Focusing on their race and ethnicity, zip code, whether they are rural or urban, and understanding the needs of those areas, how to get them enrolled in telemedicine and target specific populations. Consider whether you would like to participate. in that case. Missouri’s plan is to install kiosks in storefronts to teach people how to use iPads and access telemedicine resources so they can get services even if they can’t get to the hospital. good.

Derek van Amerongen, MD, MSc: And learn how to take advantage of that new technology.

Sharon Deans, MD, MPH, MBA: that’s right.

Derek van Amerongen, MD, MSc: Dr. Wells?

Roxy Cannon Wells, Maryland: We spend a lot of time talking about how to educate patients, but I think there is still education needed for providers, doctors, hospitals, and clinicians. And I think primary care is very important. It is a source of trust for individuals, especially black women, or women in general. I believe that is the source of trust. In our system, we work hard to ensure that only healthcare providers in general, not just primary care providers, understand the importance of clinical trials and the importance of being able to speak openly. Explain it to the patient and make sure they understand that they can participate in these clinical trials. I think it is very important not only to educate patients, but also to educate healthcare providers.

Derek van Amerongen, MD, MSc: Dr. Hawkins, any final comments?

Soini Hawkins, MD, MPH, FACOG: For us, as a private practice and at that level, it’s about culture. It’s about my staff culture. The important thing is that they understand what a trial is, and even look at and identify gaps, and at our level to make sure they don’t miss out on where they need to meet patients. It’s about how you can influence it. It’s culture. This is the culture I try to emphasize to everyone from the front desk. We intend to have Hispanic staff available for patient access when they come in and need to cross language barriers. , right down to the individuals conducting my clinical trials. I dedicate my time and effort not only to our practice, but also to our clinical trials, subjects, and patients to ensure that we are ethical and absolutely honest in all respects. We hire and invest in well-deserved people. We do that with those aspects of the trial.

Derek van Amerongen, MD, MSc: Repeat the concept of transparency.

Soini Hawkins, MD, MPH, FACOG: absolutely.

Derek van Amerongen, MD, MSc: yes. wonderful. Well, doctor, thank you very much. great discussion.

Soini Hawkins, MD, MPH, FACOG: I have a question. Do you think there are already questions and answers about why individuals don’t check boxes when it comes to race and ethnicity? , is there a fear that the information will not be recorded as it is?

Sharon Deans, MD, MPH, MBA: I think so. I think it goes back to trust, to whether or not you will be excluded from the opportunity if you answer the question, or whether your application will be accepted if you answer the question. The other thing, I think, is that it’s a bit too big-brothered, especially for Medicaid patients. Along the way, they are asked a lot of really intimate questions. There is also a little power part. That’s something they don’t have to answer. They move on to the next question. Second, the application is very complex. Not easy to navigate. I think you may be simply skipping because there are more complicated questions, or because you’ve already answered a series of complicated questions. But at the end of the day, I think it’s a question of trust, whether you’ll be marginalized, excluded, or your application taken up if you answer the question. None of it really works, but this is the environment we live in and the trust we have to build.

Roxy Cannon Wells, Maryland: I think it’s not just whether it’s excluded, but whether it’s included in something you don’t necessarily want included. I think we’ve seen that in other industries as well. It was in an area that they didn’t necessarily want to be in, whether it was banking or whatever. i think both. Will I be excluded as well? But on the other hand, does that include me?

Derek van Amerongen, MD, MSc: Great point.

I edited the transcript for clarity.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *